NASDAQ · NCNA
Healthcare · Biotechnology
$1.37
Down-$0.03 (-2.19%)
Updated Sep 10, 2026, 9:19 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NCNA closed at $1.37 after 20 trading sessions, down 4.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.40 | $1.44 | $1.37 | $1.37 | 17.2K |
| Sep 8, 2026 | $1.42 | $1.43 | $1.40 | $1.40 | 21.66K |
| Sep 4, 2026 | $1.41 | $1.42 | $1.3829 | $1.40 | 32.17K |
| Sep 3, 2026 | $1.38 | $1.44 | $1.3617 | $1.43 | 49.93K |
| Sep 2, 2026 | $1.38 | $1.425 | $1.3305 | $1.39 | 50.78K |
| Sep 1, 2026 | $1.44 | $1.45 | $1.355 | $1.38 | 103.95K |
| Aug 31, 2026 | $1.55 | $1.55 | $1.44 | $1.47 | 193.1K |
| Aug 28, 2026 | $1.45 | $1.90 | $1.41 | $1.76 | 1.02M |
| Aug 27, 2026 | $1.50 | $1.51 | $1.44 | $1.47 | 17.4K |
| Aug 26, 2026 | $1.48 | $1.53 | $1.465 | $1.53 | 13.02K |
| Aug 25, 2026 | $1.47 | $1.55 | $1.47 | $1.47 | 26.74K |
| Aug 24, 2026 | $1.52 | $1.52 | $1.47 | $1.47 | 13.41K |
| Aug 21, 2026 | $1.50 | $1.55 | $1.50 | $1.52 | 18.57K |
| Aug 20, 2026 | $1.53 | $1.55 | $1.50 | $1.53 | 18.41K |
| Aug 19, 2026 | $1.53 | $1.6599 | $1.51 | $1.55 | 26.68K |
| Aug 18, 2026 | $1.55 | $1.5872 | $1.52 | $1.52 | 17.67K |
| Aug 17, 2026 | $1.64 | $1.64 | $1.51 | $1.55 | 53.16K |
| Aug 14, 2026 | $1.49 | $1.665 | $1.49 | $1.59 | 70.88K |
| Aug 13, 2026 | $1.42 | $1.49 | $1.42 | $1.48 | 15.67K |
| Aug 12, 2026 | $1.51 | $1.51 | $1.40 | $1.43 | 18.35K |
The latest Smart Investors Daily articles mentioning NCNA.
NCNA research
Company profile and research snapshot.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2024 | Oppenheimer | Outperform | — |
| Aug 30, 2024 | William Blair | Market Perform | — |
| Aug 19, 2024 | Oppenheimer | Outperform | — |
| Jul 23, 2024 | Oppenheimer | Outperform | — |
| Jul 22, 2024 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
https://register.epo.org/application?number=EP19181028
Yahoo · Jun 11, 2026
European equities traded in the US as American depositary receipts rose late Thursday morning with t
Benzinga · Mar 20, 2026
Benzinga · Mar 20, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NCNA.
No results
No recent SID articles mention NCNA.
